Ethaselen

DB15051InvestigationalSmall molecule

Ethaselen is under investigation in clinical trial NCT02166242 (Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers).

Mechanism: Pharmacologically active on Thioredoxin reductase 1, cytoplasmic
Curator reviewed
Formula / weight: C₁₆H₁₂N₂O₂Se₂ · 422.226 g/mol (avg)

Resolves to

Compound

UNII4Q2EZS1IWGCAS217798-39-5ChEMBLCHEMBL2035460

Structure

InChIKeySFFSGPCYJCMDJM-UHFFFAOYSA-NSMILESO=C1N(CCN2[Se]C3=C(C=CC=C3)C2=O)[Se]C2=C1C=CC=C2

Targets

Q16881TXNRD1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Drug interactionStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ethaselen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account